Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.

António Cabral LopesFatima Roque Olga M LourençoMaria Teresa HerdeiroManuel Morgado

Published in: Expert opinion on drug safety (2023)

Semaglutide has a good safety profile, however the definition of subgroups within the type 2 diabetes population who are particularly prone to develop serious adverse event when treated with GLP-1 RAs is crucial.

Keyphrases

type diabetes
adverse drug
glycemic control
cardiovascular disease
wild type
newly diagnosed
emergency department
skeletal muscle
adipose tissue